Blitz Bureau
NEW DELHI: The most difficult stretch of Indian science is not the laboratory. It is the twenty metres between a working prototype and a company willing to make it. Three notices standing on the Indian Council of Medical Research’s own noticeboard this week are that stretch, in writing, with a closing date on them.
All three are invitations for expressions of interest for transfer of technology, and all three close on 4 September 2026. Read singly they are procurement notices. Read together they are a map of where Indian medical research has got to on three specific problems, and of what it is now asking Indian industry to do about them.
What is on offer
The first is a dual-tube one-step RT multiplex PCR dengue assay. Take that phrase apart and it describes a real advance. Dengue is caused by four serotypes, and which one a patient has is not a curiosity: a second infection with a different serotype is the one that turns severe. Multiplex means the test looks for more than one target in the same reaction. One-step RT means the conversion of the virus’s RNA into DNA and the amplification of that DNA happen in a single closed tube, which halves the handling and, with it, the contamination risk in a district laboratory. Dual-tube is how the targets are split so the signals stay readable. What ICMR is licensing is not the idea; it is a validated assay design.
The second is a multiplex qPCR kit that distinguishes Giardia lamblia from Entamoeba. Both are intestinal parasites, both present as persistent diarrhoea, and both are conventionally identified by a technician looking down a microscope at a stool sample — a method whose accuracy depends on how tired the technician is and how recently the sample was passed. The two organisms take different drugs. A test that tells them apart by their DNA turns a judgement call into a result.
The third is a cell culture plate with interconnected wells, and it is the quietest of the three. A standard culture plate holds cells in isolated wells. Connect the wells and you can let one cell population influence another, or let a compound move between them, which is how you begin to model an organ rather than a smear. It is a piece of laboratory hardware, of the kind India ordinarily imports.
The hardest twenty metres in Indian science are the ones between a working prototype and a company willing to make it.
ICMR’s open calls, read 2 September 2026
• Dengue assay, transfer of technology — closes 4 September
• Giardia/Entamoeba qPCR kit — closes 4 September
• Interconnected-well culture plate — closes 4 September
• Delhi TB Free Slum demonstration project — closes 4 September
• Technical Resource Centres, North-East — closes 15 September
• Viral Research and Diagnostic Laboratories — closes 30 September
• SARANSH-3 systematic review workshops — closes 30 September
From bench to factory: where these stand
This is the part that is usually left out, so it is worth being exact. A transfer-of-technology invitation is issued when the invention is finished enough to be made by somebody else and not finished enough to be a product.
The intellectual property sits with the Council; the manufacturing, the regulatory file and the distribution do not. ICMR runs a dedicated route for this, Patent Mitra, and lists the terms in each call document. What happens next is a licence, a technology transfer agreement, a manufacturer’s validation and, for the two diagnostic kits, approval by the Central Drugs Standard Control Organisation. None of that is in these notices, and none of it should be reported as though it were.
So the honest statement of the position is this: three Indian inventions are ready to be manufactured, and whether they are manufactured now depends on whether an Indian firm answers by Friday.
The other half of the same chain
Two of the Council’s other open calls belong to the same story. It is inviting proposals to set up Viral Research and Diagnostic Laboratories in medical colleges, hospitals and medical institutions, closing on 30 September 2026, and expressions of interest for Technical Resource Centres in the North-Eastern States, closing on 15 September. A diagnostic kit is only as useful as the laboratory that runs it and the person trained to read it. A council that licenses assays while simultaneously extending the network that will use them is doing the two halves of one job, and it is the second half that decides whether a district in Nagaland ever sees the first.
What India gains. Every dengue and parasite test currently run on an imported kit is a foreign exchange payment and a supply line that somebody else controls. Indian-designed, Indian-made molecular diagnostics displace both. They also travel: the ICMR network already supplies protocols and reagents beyond India’s borders through its own collaborations, and a country that exports diagnostic capability rather than importing it occupies a different position in every global health negotiation it enters. For an Indian patient the gain is smaller and more immediate — a stool test that gives a name instead of an opinion, and the right drug on the first attempt.
Offered only as corrective advice, to help the work move faster: three transfer-of-technology invitations of real commercial interest were given a window closing on 4 September, and the detail that would let a manufacturer judge them — validation data, sensitivity and specificity, the stage of regulatory readiness — sits inside the call documents rather than in the notice. A one-paragraph technical abstract on the notice itself, and a longer window on transfer-of-technology calls than on routine tenders, would widen the field of firms able to reply in time.
